COMPUGEN LTD
CGEN · XNASCIK 1119774fmd_1HYF77S0YRXZFATX2ZTVH7HSYDManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Dec 31, 2025, 32 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | – | – | – | 2 | 6 | 8 | 33 | 28 | 73 |
| Cost of revenue | 0 | – | 1 | – | 0 | 1 | 1 | 2 | 8 | 9 |
| Gross profit | 0 | – | 17 | – | 2 | 5 | 7 | 31 | 20 | 64 |
| Research and development | 25 | 29 | 30 | 20 | 23 | 29 | 31 | 34 | 25 | 23 |
| Selling, general and administrative | 7 | 8 | 8 | 8 | 10 | – | – | – | – | – |
| Total operating expenses | 33 | 37 | 40 | 29 | 33 | 40 | 42 | 44 | 35 | 32 |
| Operating income | (33) | (37) | (23) | (29) | (31) | (35) | (35) | (13) | (15) | 31 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 3 | 4 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | (31) | (37) | (23) | (28) | (30) | (34) | (34) | (10) | (10) | 35 |
| Income tax expense | 0 | – | – | (1) | 0 | 0 | 0 | 9 | 5 | 0 |
| Net income from continuing operations | (32) | – | – | (27) | (30) | (34) | (34) | (19) | (14) | 35 |
| Net income | (32) | (37) | (23) | (27) | (30) | (34) | (34) | (19) | (14) | 35 |
| Net income to common shareholders | – | – | – | – | – | – | – | (19) | (14) | 35 |